Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer.
apolipoprotein C-I
apolipoprotein C-III
diagnostic value
gastric cancer
transthyretin
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
21
09
2018
accepted:
08
01
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
15
3
2019
Statut:
ppublish
Résumé
Diagnostic value of apolipoprotein C-I (ApoC-I), transthyretin (TTR) and ApoC-III in gastric cancer were evaluated. Retrospective analysis methods were used to collect 60 patients with gastric cancer first diagnosed in The First Affiliated Hospital of Jiaxing University. There were 60 patients with chronic atrophic gastritis in the benign lesion group and 60 healthy individuals in the control group. The expression levels of serum ApoC-I, TTR and ApoC-III was detected by enzyme-linked immunosorbent assay. Differences existed in the expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group, benign lesion group and control group (P<0.001), with the expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group being lower than that of the benign lesion group (P<0.05), and the expression levels of ApoC-I, TTR and ApoC-III in the benign lesion group being lower than that of the control group (P<0.05). The expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group were to a certain degree correlated with the clinical stage, lymph node metastasis and differentiation of patients in the gastric cancer group (P<0.05). The specificity and negative predictive value of combined detection were proven to be higher than the separate detection of the three factors (P<0.05). The detection of serum ApoC-I, TTR and ApoC-III was of great significance in the diagnosis of gastric cancer and the estimation of its severity. The method of combined detection is worth a further in-depth study as it could improve the specificity of diagnosis and have a higher negative predictive value.
Identifiants
pubmed: 30867753
doi: 10.3892/ol.2019.9957
pii: OL-0-0-9957
pmc: PMC6396204
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3227-3232Références
Curr Opin Lipidol. 2001 Jun;12(3):297-304
pubmed: 11353333
Gastrointest Endosc. 2004 Nov;60(5):771-7
pubmed: 15557953
Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1580-4
pubmed: 19950835
Oncol Rep. 2010 Jul;24(1):57-64
pubmed: 20514444
Proteomics Clin Appl. 2007 Jun;1(6):536-44
pubmed: 21136704
PLoS One. 2011 Jan 18;6(1):e14540
pubmed: 21267442
Br J Cancer. 2012 Feb 14;106(4):733-9
pubmed: 22240791
Psychoneuroendocrinology. 2012 Sep;37(9):1569-76
pubmed: 22459275
Gastric Cancer. 2014 Jan;17(1):26-33
pubmed: 23572188
Int J Cancer. 2014 Jun 1;134(11):2513-22
pubmed: 23852704
World J Gastroenterol. 2014 Apr 28;20(16):4483-90
pubmed: 24782601
Surg Endosc. 2015 May;29(5):1223-30
pubmed: 25159644
Biomol Concepts. 2014 Mar;5(1):45-54
pubmed: 25372741
Gut Liver. 2015 Jan;9(1):5-17
pubmed: 25547086
Gastric Cancer. 2016 Apr;19(2):472-478
pubmed: 25752270
Oncol Lett. 2015 Apr;9(4):1502-1508
pubmed: 25788990
World J Gastroenterol. 2015 Sep 14;21(34):9838-52
pubmed: 26379391
Oman Med J. 2015 Sep;30(5):353-7
pubmed: 26421116
PLoS One. 2015 Nov 10;10(11):e0142080
pubmed: 26556485
PLoS One. 2015 Nov 13;10(11):e0142591
pubmed: 26566288
Mol Cancer. 2015 Nov 25;14:202
pubmed: 26607322
J Mass Spectrom. 2016 Jan;51(1):86-95
pubmed: 26757076
Yonsei Med J. 2016 May;57(3):549-56
pubmed: 26996551
Med Sci Monit. 2016 Apr 07;22:1152-60
pubmed: 27052600
Oncotarget. 2016 May 31;7(22):33152-64
pubmed: 27121204
Cancer Biol Ther. 2016 Jun 2;17(6):635-47
pubmed: 27260686
Clin Nutr. 2017 Apr;36(2):364-370
pubmed: 27381508
Zhonghua Yi Xue Za Zhi. 2016 Aug 23;96(32):2545-7
pubmed: 27596548
Medicine (Baltimore). 2016 Sep;95(36):e4741
pubmed: 27603371
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Oncotarget. 2017 Jun 27;8(26):42761-42771
pubmed: 28514751
Ann Surg Oncol. 2018 Apr;25(4):974-983
pubmed: 29388124
J Biochem Mol Toxicol. 2018 May 2;:e22158
pubmed: 29719090
J Surg Res. 2018 Jul;227:145-150
pubmed: 29804846
Exp Ther Med. 2018 Sep;16(3):1850-1858
pubmed: 30186410